Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -6 of 6
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
11/12/2007
 
First Published:
5/1/1999
1.
Phase II Study of Recombinant Fowlpox Virus Encoding gp100 Peptide Preceded By an Endoplasmic Reticulum Insertion Signal in Patients With Metastatic Melanoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
16 and over
NCI
NCI-99-C-0044
NCI-T98-0088, T99-0088, NCT00019669
Last Modified:
5/31/2007
 
First Published:
6/1/1999
2.
Phase II Randomized Study of Recombinant Fowlpox Prostate Specific Antigen Vaccine and Recombinant Vaccinia Prostate Specific Antigen Vaccine in Patients With Advanced Prostate Cancer (Summary Last Modified 11/2000)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
NCI
E-7897
NCT00003871, E7897
Last Modified:
5/31/2007
 
First Published:
7/1/1999
3.
Phase II Randomized Study of Recombinant Fowlpox and Vaccinia Viruses Encoding Tyrosinase Antigen in Patients With Metastatic Melanoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
16 and over
NCI
NCI-99-C-0095
NCI-T99-0025, T99-0025, NCT00019734
Last Modified:
12/3/2008
 
First Published:
5/28/2004
4.
Phase II Study of Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Comprising Fludarabine and Cyclophosphamide Followed By Autologous Lymphocyte Infusion, Recombinant Fowlpox Virus Encoding gp100 Peptide, and Aldesleukin in Patients With Recurrent or Refractory Metastatic Melanoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
16 and over
NCI
NCI-04-C-0152
NCI-6585, 6585, NCT00084500
Last Modified:
1/1/1900
5.
Phase I Study of Immunization with Recombinant Fowlpox Virus Encoding the MART-1 Melanoma Antigen with or without Concomitant IL-2 in Patients with Metastatic Melanoma (Summary Last Modified 01/00)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
over 18
NCI
NCI-95-C-0032D
NCI-T96-0026N, T96-0026
Last Modified:
4/9/2003
6.
Phase I Study of Immunization With a Recombinant Fowlpox Virus Encoding the gp100 Melanoma Antigen With or Without Concurrent Interleukin-2 in Patients With Recurrent Metastatic Melanoma (Summary Last Modified 04/2002)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
18 and over
NCI
NCI-96-C-0121
NCI-T94-0139N, T94-0139, NCT00019175
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute